GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
Diabetes & Metabolism Journal
; : 262-267, 2012.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-192549
Biblioteca responsável:
WPRO
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD), one of the most common liver diseases, is caused by the disruption of hepatic lipid homeostasis. It is associated with insulin resistance as seen in type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) is an incretin that increases insulin sensitivity and aids glucose metabolism. In recent in vivo and in vitro studies, GLP-1 presents a novel therapeutic approach against NAFLD by increasing fatty acid oxidation, decreasing lipogenesis, and improving hepatic glucose metabolism. In this report, we provide an overview of the role and mechanism of GLP-1 in relieving NAFLD.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Resistência à Insulina
/
Receptores de Glucagon
/
Diabetes Mellitus Tipo 2
/
Peptídeo 1 Semelhante ao Glucagon
/
Lipogênese
/
Incretinas
/
Fígado Gorduroso
/
Glucose
/
Homeostase
/
Hepatopatias
Idioma:
Inglês
Revista:
Diabetes & Metabolism Journal
Ano de publicação:
2012
Tipo de documento:
Artigo